One of the biggest surprises of 2020 was how biopharma M&A emerged relatively unscathed from Covid-19.
Selling its cancer drugs to Servier leaves Agios more reliant on mitapivat.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.
Evaluate Vantage's coverage of the virtual Ash 2020 congress.
And both companies’ pyruvate kinase R activators could have Global Blood looking over its shoulder, though pain crises sow doubts.
Mitapivat's pivotal win in a rare type of anaemia could bode well for its chances in thalassaemia and sickle cell disease.
Among the upcoming haematology meeting’s non-oncology presentations Uniqure’s haemophilia B gene therapy scores a valuable late-breaker.